Recorded: March 1, 2023.

Agenda:

• Introduction by Session Chair – Dr Maryam Lustberg
• CDK4/6 inhibition in HR+ MBC: Current Standard and Emerging Challenges - Dr Paolo Tarantino
• CDK4/6 Inhibitors: Toxicity Considerations - Dr Hope Rugo
• What Is Important Today? Reassessment of Goals – and Acceptance of Side Effects - Is Needed in Shared Decision Making - Dr Kelly Shanahan (Patient Partner)
• Case Study & Panel Discussion

Objectives:

• To improve the understanding of clinicians in identifying which CDK 4/6 treatment to choose in taking a shared decision approach
• The patient experience of targeted therapy toxicities and how it impacts quality of life, adherence, and disease outcomes
• Identify innovative strategies to optimally manage related toxicities with CDK4/6 inhibitors in patients with breast cancer

Learner Outcomes:

• How to make personalized treatment decisions for patients with hormone receptor positive breast cancer who are candidates for CDK 4/6 inhibitors
• How to improve supportive care strategies for patients with breast cancer who are undergoing targeted therapy
• Address in knowledge in management and how to best deliver multi D care for cancer survivors of all stages.

This webinar is made possible by an unrestricted educational grant provided by Pfizer.